Shionogi announced that it had received approval in Japan for the additional dosage and administration of carbapenem antibiotic products.
Shionogi & Co., Ltd., a leading company of anti-infective drugs, announced last week that it had received approval in Japan for the additional dosage and administration of “Finibax? 0.25g IV Solution” and "Finibax? 0.25g IV Solution Kit” (generic name: doripenem hydrate), carbapenem antibiotic products, which allows the products to be administered 3g as a maximum daily dose.
"Finibax? 0.25g IV Solution”, launched in September, 2005 in Japan, is a parenteral injection of carbapenem antibiotic discovered and developed by Shionogi and exhibits a strong and broad antibacterial spectrum, covering gram-positive to gram-negative bacteria as well as aerobic to anaerobic bacteria. Since this antibiotic has a strong antibacterial activity against Pseudomonas aeruginosa, which causes a remedial problem as one of offending bacteria of serious and intractable infections, it has been prescribed with high usability in treating various types of moderate to serious infections.
Finibax?/Doribax? have already been approved in 78 countries of the world and the approval of the maximum daily dose of 3g in Japan is the first achievement in the world.
